Company profile
GeNeuro SA
The therapeutic substances from GeNeuro fight illnesses such as multiple sclerosis right at their roots. They prevent the processes that eventually lead to brain damage and invalidity. The first substances are already in the clinical phase and are being tested on healthy volunteers. www.geneuro.com
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
